HRQOL improvements in anemic CKD patients treated with darbepoetin alfa (Aranesp™)

被引：0

作者：

Ruhman, SN

Heifner, KJ

Fadem, SZ

Melvor, ME

Brenner, RM

Powers, KM

Ford, JM

机构：

[1] Amgen Inc, Thousand Oaks, CA 91320 USA

[2] St Petersburg Heart Ctr, St Petersburg, FL USA

[3] Huston Kidney Ctr, Houston, TX USA

[4] Renal Associates, Little Rock, AR USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2002年 / 39卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：A27 / A27

页数：1

共 50 条

[1] Hemoglobin responses following darbepoetin alfa (Aranesp®) vs. epoetin alfa (Procrit®) administration in anemic chronic kidney disease (CKD) patients
Sarac, E
Veres, Z
Schuler, E
Tallum, S
Gemmel, DJ
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V264 - V264
[2] Pharmacokinetics (PK) of Aranesp® (darbepoetin alfa) in patients with chronic kidney disease (CKD)
Padhi, D
Jang, G
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 : V255 - V255
[3] Treatment of anemia with Aranesp™ (darbepoetin alfa) improves health related quality of life (HRQOL) in patients with chronic kidney disease (CKD).
Thadhani, R
Cheriyan, R
Brenner, R
Ford, J
Powers, K
Rahman, SN
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 637A - 637A
[4] Aranesp® (darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease (CKD).
Walczyk, M
Agarwal, A
Ling, B
Carroll, W
Liu, W
Brenner, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2003, 41 (04) : A38 - A38
[5] Aranesp® (Darbepoetin alfa) administered once monthly maintains hemoglobin levels in patients with chronic kidney disease (CKD).
Agarwal, A
Ling, B
Walczyk, M
Carroll, W
Liu, W
Brenner, R
AMERICAN JOURNAL OF KIDNEY DISEASES, 2004, 43 (04) : A15 - A15
[6] Anemia management preferences in chronic kidney disease (CKD) patients converted to oncemonthly (QM) ARANESP® (darbepoetin alfa)
Vainer, A
Hoggard, J
Koenig, K
Prathikanti, R
Scarlata, D
Globe, D
Audhya, P
AMERICAN JOURNAL OF KIDNEY DISEASES, 2005, 45 (04) : A54 - A54
[7] Clinical experience with darbepoetin-alfa (Aranesp®)
Locatelli, F
Del Vecchio, L
Marai, P
HEMODIALYSIS TECHNOLOGY, 2002, 137 : 403 - 407
[8] Darbepoetin alfa (Aranesp) as supportive therapy in patients with germ cell tumors
Rexer, H.
UROLOGE, 2006, 45 (08): : 1017 - 1018
[9] ECONOMIC EVALUATION OF EPOETIN ALFA HEXAL (BINOCRIT) COMPARED TO DARBEPOETIN ALFA (ARANESP) IN THE TREATMENT OF CHRONIC HAEMODIALYSIS (CKD5) PATIENTS IN GERMANY
Turner, M.
Walsh, K.
Maerz, M.
Whitehouse, J.
VALUE IN HEALTH, 2013, 16 (07) : A631 - A631
[10] Darbepoetin alfa (Aranesp™) in children with chronic renal failure
Geary, DF
Keating, LE
Vigneux, A
Stephens, D
Hébert, D
Harvey, EA
KIDNEY INTERNATIONAL, 2005, 68 (04) : 1759 - 1765

← 1 2 3 4 5 →